Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Gut PC

Neither a doctor nor a teaching hospital

Research payments

$549,336

203 payments

Through program year 2025, Gut PC is reported as receiving $549,336 in research payments, across 203 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $155,670 58
2024 Research $96,842 47
2023 Research $110,290 39
2022 Research $144,737 41
2021 Research $11,894 4
2020 Research $7,440 2
2019 Research $22,463 12

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $205,542 110 payments
  2. Arena Pharmaceuticals, Inc. $200,037 58 payments
  3. Genentech, Inc. $75,574 25 payments
  4. AbbVie, Inc. $36,925 4 payments
  5. Gilead Sciences, Inc. $16,000 2 payments
  6. F. Hoffmann-La Roche AG $15,257 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. An Openlabel Extension Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis $123,844 67 payments
  2. A Randomized Doubleblind Placebocontrolled 52Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis $111,269 30 payments
  3. A Multicenter Randomized Doubleblind Parallelgroup Study to Assess the Efficacy and Safety of Oral Etrasimod As Induction and Maintenance Therapy for Moderately to Severely Active Crohns Disease $59,274 24 payments
  4. UC P3: Double-Blind Treat Straight Through $53,533 16 payments
  5. A Phase 2 Randomized Doubleblind Placebocontrolled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis $49,571 13 payments
  6. A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) $25,841 7 payments
  7. A Phase 2B Doubleblind Randomized Placebocontrolled Parallel Group Dose Ranging Study of Oral Pf06651600 and Pf06700841 As Induction and Chronic Therapy in Subjects With Moderate to Severe Ulcerative Colitis $25,796 16 payments
  8. A Phase 3 Randomized Doubleblind Placebocontrolled 12Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis $24,757 12 payments
  9. A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) $14,900 1 payment
  10. Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) $12,199 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record